BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 17341666)

  • 1. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.
    Epling-Burnette PK; Bai F; Painter JS; Rollison DE; Salih HR; Krusch M; Zou J; Ku E; Zhong B; Boulware D; Moscinski L; Wei S; Djeu JY; List AF
    Blood; 2007 Jun; 109(11):4816-24. PubMed ID: 17341666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.
    Carlsten M; Baumann BC; Simonsson M; Jädersten M; Forsblom AM; Hammarstedt C; Bryceson YT; Ljunggren HG; Hellström-Lindberg E; Malmberg KJ
    Leukemia; 2010 Sep; 24(9):1607-16. PubMed ID: 20613786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes of natural kill cell in peripheral blood of patients with myelodysplastic syndrome].
    Mi H; Fu R; Wang H; Qu W; Ruan E; Wang X; Wang G; Liu H; Wu Y; Song J; Xing L; Guan J; Li L; Jiang H; Zhang W; Yue L; Shao Z
    Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(10):737-41. PubMed ID: 24844955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Cianga VA; Campos Catafal L; Cianga P; Pavel Tanasa M; Cherry M; Collet P; Tavernier E; Guyotat D; Rusu C; Aanei CM
    Front Immunol; 2021; 12():665541. PubMed ID: 33986753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow mesenchymal stem cells regulate the dysfunction of NK cells via the T cell immunoglobulin and ITIM domain in patients with myelodysplastic syndromes.
    Liu Z; Guo Y; Huang L; Jia Y; Liu H; Peng F; Duan L; Zhang H; Fu R
    Cell Commun Signal; 2022 Oct; 20(1):169. PubMed ID: 36303184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
    Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
    Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
    Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
    Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes.
    Kiladjian JJ; Bourgeois E; Lobe I; Braun T; Visentin G; Bourhis JH; Fenaux P; Chouaib S; Caignard A
    Leukemia; 2006 Mar; 20(3):463-70. PubMed ID: 16408099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
    Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
    Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
    Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
    Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias.
    Nowbakht P; Ionescu MC; Rohner A; Kalberer CP; Rossy E; Mori L; Cosman D; De Libero G; Wodnar-Filipowicz A
    Blood; 2005 May; 105(9):3615-22. PubMed ID: 15657183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
    Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
    Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expressions of CD96 and CD123 in Bone Marrow Cells of Patients with Myelodysplastic Syndromes.
    Zhang W; Shao Z; Fu R; Wang H; Li L; Liu H
    Clin Lab; 2015; 61(10):1429-34. PubMed ID: 26642704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes.
    Hua Y; Wang C; Jiang H; Wang Y; Liu C; Li L; Liu H; Shao Z; Fu R
    Int J Hematol; 2017 Aug; 106(2):248-257. PubMed ID: 28405919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
    Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
    Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
    Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
    Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes.
    Sawanobori M; Yamaguchi S; Hasegawa M; Inoue M; Suzuki K; Kamiyama R; Hirokawa K; Kitagawa M
    Leuk Res; 2003 Jul; 27(7):583-91. PubMed ID: 12681357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT/CD155 pathway.
    Yue J; Li J; Ma J; Zhai Y; Shen L; Zhang W; Li L; Fu R
    Hematology; 2023 Dec; 28(1):2166333. PubMed ID: 36651499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.
    Garcia-Iglesias T; Del Toro-Arreola A; Albarran-Somoza B; Del Toro-Arreola S; Sanchez-Hernandez PE; Ramirez-Dueñas MG; Balderas-Peña LM; Bravo-Cuellar A; Ortiz-Lazareno PC; Daneri-Navarro A
    BMC Cancer; 2009 Jun; 9():186. PubMed ID: 19531227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML.
    Schlegel P; Ditthard K; Lang P; Mezger M; Michaelis S; Handgretinger R; Pfeiffer M
    J Immunol Res; 2015; 2015():473175. PubMed ID: 26236752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.